BCM
WHWK

BML Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

BML Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,890,245
Closed -$3.36M – 28
2025
Q1 		$3.36M Sell
1,890,245
-209,755
-10% -$548K 2.72% 11
2024
Q4 		$6.63M Buy
2,100,000
+100,000
+5% +$227K 4.12% 8
2024
Q3 		$4.12M Buy
+2,000,000
New +$3.23M 2.42% 12

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BML Capital Management's WHWK Position: Q2 2025 in Review

BML Capital Management sold out of Whitehawk Therapeutics (WHWK) in Q2 2025, closing a stake of 1,890,245 shares — an estimated $3.36M sold.

BML Capital Management first reported a position in WHWK in Q3 2024 and held it in 3 quarters. The position peaked at $6.63M in Q4 2024. 39 funds tracked by Wall St. Rank hold WHWK as of Q2 2025.

  • BML Capital Management reported no remaining Whitehawk Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BML Capital Management sold 1,890,245 Whitehawk Therapeutics shares in Q2 2025, an estimated $3.36M.
  • BML Capital Management first reported a position in Whitehawk Therapeutics in Q3 2024 and held it in 3 quarters.
  • BML Capital Management's Whitehawk Therapeutics position peaked at $6.63M in Q4 2024.
  • 39 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2025.

Based on BML Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.